Incyte’s Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing
This article was originally published in Pharmaceutical Approvals Monthly
The profile and potential of Incyte Corp.’s ruxolitinib (INCB18424) in myelofibrosis came into sharper focus with the release of detailed data from two major trials at the American Society of Clinical Oncology meeting and announcement of an FDA filing.
You may also be interested in...
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.
No time to lose: A deal for an earlier-stage oral drug underscores Big Pharma's passion for new targets in inflammatory diseases.
The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.